Ucb S.a. · EURONEXT:UCB
Ucb — Merger or Acquisition (January 2022)
22 slides from Ucb's merger presentation, Jan 19, 2022
Slide 1: UCB to Acquire Zogenix
UCB to Acquire Zogenix Committed to Improving Lives of People Living with Epilepsy Capital Markets Conference Call 19 January 2022
Slide 2: Important Information About the Tender Offer
Important Information About the Tender Offer 2 The tender offer described in this document (the “Offer”) has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of Zogenix, Inc.
Slide 3: Disclaimer
Disclaimer 3 Forward-Looking Statements This presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, and “continue” and similar expressions, the abi
Slide 4: Agenda
Information Flow 4 ןUCB is Progressing on its Strategic Growth Path • Jean-Christophe Tellier, CEO ןUCB and Zogenix Serving People Living with Epilepsy • Charl van Zyl, EVP Head of Neurology ןEpilepsy – Dravet Syndrome and Lennox-Gastaut Syndrome • Iris Loew-Friedrich, CMO ןTransaction T
Slide 5: UCB is Progressing on its Strategic Growth Path
5 UCB is Progressing on its Strategic Growth Path Jean-Christophe Tellier, CEO
Slide 6: UCB Is Progressing On Its Strategic Growth Path
UCB Is Progressing On Its Strategic Growth Path 6 Identify & Act On Potential New Opportunities Builds upon UCB’s role as a leader and continued commitment to addressing the unmet needs of people living with epilepsy Strategic Missions Zogenix Acquisition Option for new specific, vulnerable Provide
Slide 7: Recognized as a leader in epilepsy with differentiated portfolio
Recognized as a leader in epilepsy with core competencies, 2019 HY report - 7 UCB key strategic focus and differentiated portfolio UCB’s • To bring tailored treatments to specific populations, incl. rare epilepsies and genetic commitment epilepsies Strong • FINTEPLA®: Fenfluramine oral solution in D
Slide 8: UCB and Zogenix Serving People Living with Epilepsy
8 UCB and Zogenix Serving People Living with Epilepsy Charl van Zyl, EVP Head of Neurology Jerome, living with epilepsy
Slide 9: UCB: Over 20 Years of R&D Expertise and Commercial Success
UCB: 9 Over 20 Years of R&D Expertise and Commercial Success • Enrolled >25 000 patients in >250 clinical studies for more than 10 epilepsy conditions • Current phase 3 program: Staccato alprazolam in active epileptic seizures • New indications by innovative clinical development-extrapolation • 2021
Slide 10: UCB's Epilepsy Strategy
UCB’s Epilepsy Strategy 10 Delivering Value for Patients • Our ambition is to redefine the future of epilepsy medicine, aspiring to bring even greater value to people living with seizures • Utilizing our experience and expertise to develop new differentiated medicines and technology support solution
Slide 11: Zogenix, Inc.: Committed to Innovative Therapies
Zogenix, Inc.: Committed to Innovative Therapies 11 Helping Those Most in Need: Children Living with Dravet Syndrome and Other Rare Neurologic Indications Lead product FINTEPLA® fenfluramine oral solution • Orphan drug designation in US/EU/JPN for Dravet Syndrome HQ: San Francisco Bay Area, CA/USA •
Slide 12: Excellent Strategic Fit with UCB
Excellent Strategic Fit with UCB 12 Augments UCB’s Offering by Adding New Patient Populations Acquires "possible best in class" treatment option Builds on UCB’s focus on epilepsy and ambitions to bring even greater value to people living with seizures Creating value Enhances epilepsy offering & rare
Slide 13: Epilepsy – Dravet Syndrome and Lennox-Gastaut Syndrome
13 Epilepsy – Dravet Syndrome and Lennox-Gastaut Syndrome Iris Loew-Friedrich, CMO Jerome, living with epilepsy
Slide 14: Epilepsy: Paradigm Shift From Suppression of Seizures to Disease Modification
14 Evolving from broad to specific populations according to patient needs and disease biology Paradigm Shift From Suppression of Seizures to Disease Modification Mixed Acute Seizure Therapy / Medically Prodromes Controllable Other DEE 70% Dravet Genetic or developmental Syndromes Paradigm shift for
Slide 15: Dravet Syndrome
Dravet Syndrome 15 A Rare and Often Fatal Epilepsy with Early Onset Early onset • About 200-250 infants/year; ~20k patients in both the U.S. and EU5 • Most cases are due to severe SCN1A gene mutations (90% de novo) • Onset in the 1st year of life in an otherwise healthy infant Highly • Rare, drug-re
Slide 16: FINTEPLA Fenfluramine Oral Solution
FINTEPLA® 16 Fenfluramine Oral Solution • Approved in U.S. and EU in 2020 for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age and older • Three positive global Phase 3 trials completed (US, EU, JPN) • Data published in the Lancet December 2019 • Ongoing open labe
Slide 17: Lennox-Gastaut Syndrome (LGS)
Lennox-Gastaut Syndrome (LGS) 17 A Rare Syndrome in Epilepsy with Childhood-Onset* Early onset • 60,000-100,000 living with LGS in the U.S. and Europe • Caused by injuries, brain malformations, infections, genetic factors; unknown cause in 25% of cases • Childhood onset, accounts for ~1- 4% of all c
Slide 18: Transaction Terms, Funding & Timing
Transaction Terms, Funding & Timing Sandrine Dufour, CFO
Slide 19: Compelling Value Proposition for all Stakeholders
Compelling Value Proposition for all Stakeholders 19 Terms Upon Closure of the Transaction Consideration • Zogenix’ shareholders to receive US$ 26 per share in cash at closing • Plus a CVR for a potential cash payment of US$ 2.00 per share based on EU LGS approval for FINTEPLA® designated as an orph
Slide 20: Excellent Strategic Fit with UCB
Excellent Strategic Fit with UCB 20 Combining Forces to Better Serve People Living with Epilepsy • Maximizes impact of UCB’s and Zogenix’s teams and infrastructure, expertise and experience • Strengthens epilepsy offering and rare diseases at UCB • Maximizes addressable patient population • Integrat
Slide 21: Q&A
Q&A Antje Witte, Head of Investor Relations
Slide 22: Inspired by patients. Driven by science.
rN wy nspired by patients. Driven by science.